Glenmark Pharmaceuticals rises as its arm launches Sugammadex Injection
Glenmark Pharmaceuticals is currently trading at Rs. 2212.05, up by 27.15 points or 1.24% from its previous closing of Rs. 2184.90 on the BSE.
The scrip opened at Rs. 2209.05 and has touched a high and low of Rs. 2,216.00 and Rs. 2,188.70 respectively. So far 165 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2471.05 on 29-Apr-2026 and a 52 week low of Rs. 1794.00 on 28-Oct-2025.
Last one week high and low of the scrip stood at Rs. 2242.25 and Rs. 2,179.40 respectively. The current market cap of the company is Rs. 61658.05 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.53% and 13.81% respectively.
Glenmark Pharmaceuticals’ wholly-owned subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has launched Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark’s Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION Injection, 100 mg/mL of Merck Sharp & Dohme LLC.
According to IQVIA sales data for the 12-month period ending May 2026, the BRIDION Injection, 100 mg/mL market achieved annual sales of around $1.6 billion.
